-
Daiichi Sankyo2020-08-03 09:25:16Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with HER2
-
Daiichi Sankyo2020-08-03 09:25:37Bempedoic Acid Lowers LDL-Cholesterol without Adversely Impacting Glycaemic Control in Pooled Analyses of
-
Daiichi Sankyo2020-08-03 09:26:30Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom
-
Daiichi Sankyo2020-08-03 09:27:20Daiichi Sankyo Data at ASH Showcases Scientific and Clinical Advancements Across AML/Blood Cancer Portfolio
-
Daiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate
-
Daiichi Sankyo2020-08-03 09:28:15Pooled Analyses of Bempedoic Acid Phase 3 LDL-C Lowering Clinical Trial Programme to be Presented at the
-
Daiichi Sankyo2020-08-03 09:28:51Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration
-
Daiichi Sankyo2020-08-03 09:29:33Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with
-
Daiichi Sankyo2020-08-03 09:30:09[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2
-
Daiichi Sankyo2020-08-03 09:30:42European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly